J&J says Phase 3 ICONIC-LEAD trial shows ICOTYDE sustains psoriasis clearance through 2 years
JNJ•Johnson & Johnson said Phase 3 ICONIC-LEAD results showed ICOTYDE sustained skin clearance and itch improvement in adults and adolescents through two years, with no new safety concerns flagged.
1. Two-year results
Johnson & Johnson disclosed two-year results from the Phase 3 ICONIC-LEAD trial of oral psoriasis drug ICOTYDE, which had been presented at Fall Clinical Dermatology 2026. The study showed durable skin clearance and sustained itch improvement in adults and adolescents; patients who stopped treatment and later restarted generally regained strong disease control within months. The safety profile remained consistent, with no new safety concerns flagged.
